Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial
Pelubiprofen at 45 mg provided superior short-term analgesic efficacy compared with placebo and was generally well tolerated in women with primary dysmenorrhea.
Authors
- Kyong Wook Yi (ORCID: https://orcid.org/0000-0001-7059-640X)
- Jong Kil Joo (ORCID: https://orcid.org/0000-0002-6338-1512)
- SiHyun Cho (ORCID: https://orcid.org/0000-0003-2718-6645)
- Jung Ryeol Lee (ORCID: https://orcid.org/0000-0003-3743-2934)
- Dongyun Lee (ORCID: https://orcid.org/0000-0003-1941-4708)
- Joo Hyun Park (ORCID: https://orcid.org/0000-0001-6388-5975)
- Sang Ho Yoon (ORCID: https://orcid.org/0000-0003-1754-2212)
- Sung Pil Choo (ORCID: https://orcid.org/0000-0002-7852-490X)
- Inha Lee
- Young Sik Choi
- Seung Hwa Hong
- Mi Ran Kim
- Hyun Tae Park
- Sung Hoon Kim
Institutions
- Seoul National University (KR)
- Yonsei University (KR)
- Korea University (KR)
- Dongguk University (KR)
- Severance Hospital (KR)
- Samsung Medical Center (KR)
- University of Ulsan (KR)
- Pusan National University Hospital (KR)
- Gangnam Severance Hospital (KR)
- Inha University Hospital (KR)
- Chungbuk National University Hospital (KR)
- Ajou University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-03-31
- DOI
- https://doi.org/10.3390/jcm15072658
- Primary Topic
- Menstrual Health and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00